Acute respiratory distress syndrome (ARDS) is a clinical syndrome consisting of tachypnea, refractory hypoxemia, and diffuse opacities on chest radiographs after infection or trauma which ultimately leads to respiratory failure. The principles of treatment are based on patient care in ICU, mechanical ventilation and medical treatments. By using lower plateau, less tidal volume, higher positive end-expiratory pressure, fluid restriction, treatment of infections and avoiding any high-dose steroids can improve the survival of these patients. In this paper, we present a case of ARDS in a patient with suspected influenza.
Introduction
cute respiratory distress syndrome (ARDS) is a clinical syndrome characterized by rapidly progressive hypoxemia, tachypnea, and then quickly evolves into respiratory failure. The underlying mechanism is diffuse lung damage. Diagnostic criteria include acute onset, profound hypoxemia, bilateral pulmonary infiltrates, and the absence of left atrial hypertension. Diagnosis is based on an partial pressure of arterial oxygen to percentage of inspired oxygen (PaO 2 /FIO 2 ) ratio of less than 300 mmHg despite a positive end-expiratory pressure (PEEP) of more than 5 cmH2O.
to the intensive care unit (ICU) with a presumptive diagnosis of viral or bacterial community-acquired pneumonia. Laboratory results showed leukocytosis (14200/µL) and significant increase of C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) ( Table 1 ).
The initial empirical antibacterial therapy with ceftriaxone, azithromycin and oseltamivir was started but he developed a severe respiratory failure unresponsive to non-invasive oxygenation techniques and required intubation and mechanical ventilation (MV). Bacterial cultures of blood, urine and tracheal aspirate were negative. The electrocardiogram result was normal and echocardiography showed the normal contractility of both ventricles without any signs of right ventricular failure.
A nasal swab tested with polymerase chain reaction (PCR) was negative for H1N1 swine flu virus. Nine days after admission, blood gas analysis showed hypoxemia, respiratory acidosis with partial pressure of carbon dioxide (PaCO 2 ) of 54 mmHg and bicarbonate of 29 mEqu/L and the chest X-ray showed diffuse, patchy bilateral infiltrates. During this phase, the modality of MV was changed from synchronized intermittent mandatory ventilation (SIMV) to high-level PEEP (14 cmH 2 O). Eleven days after admission, a pulmonary superinfection by multidrug-resistant acineto-bacter was diagnosed and the initial antibacterial therapy was substituted by the association of parenteral high-dose ampicillin-sulbactam. This treatment led to a progressive improvement of the patient's clinical status. Weaning from the ventilator was difficult due to a persistently very low respiratory system compliance: The overall duration of MV was 22 days. The patient was discharged from the ICU 35 days after admission.
Discussion
Most cases of ARDS in adults are associated with sepsis and pneumonia [4] .
Diagnosis
Because the presenting symptoms of ARDS are nonspecific, physicians must consider other respiratory, cardiac, infectious, and toxic etiologies. Patient history in conjunction with a physical examination can help narrow the differential diagnosis. Acute eosinophilic pneumonia manifested with fever, cough, diffuse infiltrates and increased eosinophils on bronchoalveolar lavage was the important differential diagnosis of our case [6] . 
Treatments
Treatment of the underlying cause is crucial. Appropriate antibiotic therapy should be started as soon as culture results are available, or if infection is suspected. Patients with ARDS should receive prophylaxes for the prevention of venous thromboembolism, stress ulcer and pressure ulcer. Finally, patients should receive nutritional support, preferably enteral within 24-48 hours of admission to the ICU [5] .
Pharmacological treatments
There is no evidence that any medication can decrease morbidity and mortality rate in people with ARDS [8] .
Most of studies demonstrated that corticosteroids are not effective for the treatment of ARDS [9] .
Fluid management
Several studies have shown that pulmonary function and clinical outcome are better in ARDS patients with fluid restriction [10] .
Mechanical ventilation
ARDS is usually treated with MV in ICU. MV is usually delivered through endotracheal intubation, or by tracheostomy when prolonged ventilation is necessary. The overall goal of MV is to maintain acceptable gas exchange to meet the body's metabolic demands and to minimize its adverse effects. Studies have shown that high tidal volume (VT) can overstretch alveoli resulting in volume trauma. Low VT ventilation and plateau pressure less than 30 cm H 2 O were the independent variables associated with reduced mortality in ARDS.
PEEP is used in mechanically ventilated people with ARDS to improve oxygenation. High PEEP can be harmful; it necessarily increases alveolar pressure which can damage normal alveoli. MV strategies that use lower end-inspiratory (plateau) airway pressures, lower VT, and higher PEEPs (lung-protective MV) are associated with survival benefits in randomized clinical trials involving patients with ARDS. The ratio of respiratory rate to tidal volume with a value ≤105 is one of the most important weaning parameters [13] .
Conclusion
The primary treatment of ARDS involves MV along with treatments directed based on the underlying cause. The lung-protective MV, restrictive fluid resuscitation strategies, adequate empiric antimicrobial therapy and source control, aspiration precautions, assessing readiness for ex-tubation, limiting on-going sedation, and performing spontaneous breathing trial as soon as possible can increase the survival rate of patients with ARDS.
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